WO2005079817A1 - Heparine/heparane sulfate purifie a affinite destine a la regulation de l'activite biologique du recepteur fgf - Google Patents

Heparine/heparane sulfate purifie a affinite destine a la regulation de l'activite biologique du recepteur fgf Download PDF

Info

Publication number
WO2005079817A1
WO2005079817A1 PCT/US2005/005012 US2005005012W WO2005079817A1 WO 2005079817 A1 WO2005079817 A1 WO 2005079817A1 US 2005005012 W US2005005012 W US 2005005012W WO 2005079817 A1 WO2005079817 A1 WO 2005079817A1
Authority
WO
WIPO (PCT)
Prior art keywords
fgf7
fgf
substantially purified
activity
affinity
Prior art date
Application number
PCT/US2005/005012
Other languages
English (en)
Inventor
Wallace L. Mckeehan
Yongde Lu
Original Assignee
The Texas A & M University System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Texas A & M University System filed Critical The Texas A & M University System
Publication of WO2005079817A1 publication Critical patent/WO2005079817A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan

Abstract

L'invention concerne des procédés et des compositions permettant de moduler l'activité d'un récepteur FGF chez un mammifère. Les procédés et compositions mettent en oeuvre des oligosacchardides d'héparine/héparane sulfate (HS) sensiblement purifiés possédant une affinité pour FGF7. Le HS possédant une affinité élevée pour FGF7 présente une activité accrue pour la promotion de la formation d'un complexe FGF/HS/FGFR ternaire. Selon un mode de réalisation de l'invention, un HS sensiblement purifié est un octasaccharide possédant 7 ou 8 sulfates et possédant une composition de disaccharide prédominant de ?HexA2SG1cN6S et un disaccharide tri-sulfaté. Dans un autre mode de réalisation, le HS sensiblement purifié est un oligosaccharide plus long présentant un motif structurel d'octasaccharide possédant 7 ou 8 sulfates et possédant une composition de disaccharide prédominant de ?HexA2SG1cN6S et un disaccharide tri-sulfaté.
PCT/US2005/005012 2004-02-18 2005-02-17 Heparine/heparane sulfate purifie a affinite destine a la regulation de l'activite biologique du recepteur fgf WO2005079817A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60/345,377 2001-11-09
US34537704P 2004-02-18 2004-02-18

Publications (1)

Publication Number Publication Date
WO2005079817A1 true WO2005079817A1 (fr) 2005-09-01

Family

ID=34885829

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/005012 WO2005079817A1 (fr) 2004-02-18 2005-02-17 Heparine/heparane sulfate purifie a affinite destine a la regulation de l'activite biologique du recepteur fgf

Country Status (1)

Country Link
WO (1) WO2005079817A1 (fr)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034520A (en) * 1986-04-17 1991-07-23 Sanofi Process for recovering heparinic oligosaccharides with an affinity for cell growth factors
WO1993019096A1 (fr) * 1992-03-23 1993-09-30 Cancer Research Campaign Technology Limited Oligosaccharides presentant une affinite de liaison au facteur de croissance
WO2001040267A2 (fr) * 1999-12-05 2001-06-07 Yeda Research And Development Co. Ltd. Proteoglycanes et compositions pharmaceutiques les renfermant
US20020111331A1 (en) * 2000-11-21 2002-08-15 Mckeehan Wallace L. FGF-affinity chromatography

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5034520A (en) * 1986-04-17 1991-07-23 Sanofi Process for recovering heparinic oligosaccharides with an affinity for cell growth factors
WO1993019096A1 (fr) * 1992-03-23 1993-09-30 Cancer Research Campaign Technology Limited Oligosaccharides presentant une affinite de liaison au facteur de croissance
WO2001040267A2 (fr) * 1999-12-05 2001-06-07 Yeda Research And Development Co. Ltd. Proteoglycanes et compositions pharmaceutiques les renfermant
US20020111331A1 (en) * 2000-11-21 2002-08-15 Mckeehan Wallace L. FGF-affinity chromatography

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GUIMOND SCOTT E ET AL: "Fibroblast growth factor receptor signalling is dictated by specific heparan sulphate saccharides", CURRENT BIOLOGY, vol. 9, no. 22, 18 November 1999 (1999-11-18), pages 1343 - 1346, XP002329007, ISSN: 0960-9822 *
JANG JUN-HYEOG ET AL: "Heparan sulfate is required for interaction and activation of the epithelial cell fibroblast growth factor receptor-2IIIb with stromal-derived fibroblast growth factor-7", IN VITRO CELLULAR AND DEVELOPMENTAL BIOLOGY ANIMAL, vol. 33, no. 10, November 1997 (1997-11-01), pages 819 - 824, XP009047865, ISSN: 1071-2690 *
LAROCHELLE W J ET AL: "Heparan Sulfate Proteoglycan Modulates Keratinocyte Growth Factor Signaling through Interaction with both Ligand and Receptor", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, PA, US, vol. 38, 16 January 1999 (1999-01-16), pages 1765 - 1771, XP002187432, ISSN: 0006-2960 *
OSTROVSKY OLGA ET AL: "Differential effects of heparin saccharides on the formation of specific fibroblast growth factor (FGF) and FGF receptor complexes", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 277, no. 4, 25 January 2002 (2002-01-25), pages 2444 - 2453, XP002329006, ISSN: 0021-9258 *
YAMADA S; SUGAHARA K: "Structure of oligosaccharides isolated from heparan sulfate/heparin and substrate specificities of the degrading enzymes of bacterial origin", TRENDS IN GLYCOSCIENCE AND GLYCOTECHNOLOGY, vol. 10, no. 52, March 1998 (1998-03-01), pages 95 - 123, XP002329009 *

Similar Documents

Publication Publication Date Title
US10245281B2 (en) Glycosaminoglycans
KR100591960B1 (ko) 황산화된올리고사카라이드의제조및그용도
US20060183712A1 (en) Affinity purified heparin/heparan sulfate for controlling the biological activity of the FGF receptor
EP0394971A1 (fr) Inhibiteurs de croissance de cellules endothéoliales et d'angiogénèse contenant un oligosaccharide
KR100855331B1 (ko) 혈관형성 억제 활성을 가지며 응고억제 효과는 없는,헤파라나제 억제제로서 부분적으로 탈황산화된글리코스아미노글리칸의 유도체
JPH01503548A (ja) ヘパリン誘導体
CN110446511B (zh) 短效的基于肝素的抗凝血剂化合物和方法
CA2132750A1 (fr) Oligosaccharides presentant une grand affinite de liaison avec des facteurs de croissance
JP4262979B2 (ja) Ｆｇｆアフィニティークロマトグラフィー
AU694177B2 (en) Non-anticoagulant chemically modified heparinoids for treating hypovolemic shock and related shock syndromes
JP6741277B2 (ja) 硫酸化ヘパリン由来オリゴ糖及びその調製法と施用
WO2009013162A1 (fr) Procédé de préparation d'hyaluronates sulfatés inhibiteurs de l'héparanase et produits obtenus de cette façon
AU700451B2 (en) Highly sulfated maltooligosaccharides with heparin-like properties
EP1731131A1 (fr) Accelerateur de production hgf contenant un oligosaccharide de type heparine
US6569840B1 (en) Low-molecular heparin modification and remedy for skin ulcer
El-Safory et al. Cytotoxic and antioxidant effects of unsaturated hyaluronic acid oligomers
JP2011526608A (ja) グリコサミノグリカンを含む医薬組成物及び慢性潰瘍の処理へのその使用
EP1746108A1 (fr) Chaîne hybride chondroïtine sulfate/dermatan sulfate provenant du poisson
JPH0273019A (ja) 多環性芳香族化合物を含有する医薬品合成物
WO2005079817A1 (fr) Heparine/heparane sulfate purifie a affinite destine a la regulation de l'activite biologique du recepteur fgf
JPH0153650B2 (fr)
CN108117615B (zh) 低分子量肝素以及肝素用于制备治疗肺纤维化药物的用途
Luo et al. Biospecific extraction and neutralization of anticoagulant heparin with fibroblast growth factors (FGF)
KR100594567B1 (ko) 헤파리나제 효소 활성을 저해하는 상제논 ｃ와 상제논 ｇ
CN108117614B (zh) 低分子量肝素

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase